Search research articles
Contact Us
Filters
Showing results (1-10 of 25) with videos related to
Page
of 3
Sort By:
Best Practice & Research. Clinical Endocrinology & Metabolism
|
December 7, 2007
Inhaled insulin
Sabine Arnolds, Tim Heise
Lancet (London, England)
|
August 5, 2008
Basal insulin glargine vs prandial insulin lispro in type 2 diabetes
Sabine Arnolds, Klaus Rave
Diabetes Care
|
January 24, 2015
Comment on Retnakaran et al. Liraglutide and the preservation of pancreatic β-cell function in early type 2 diabetes: the LIBRA trial. Diabetes Care 2014;37:3270-3278
Sabine Arnolds, Peter T Sawicki
Journal of Diabetes Science and Technology
|
June 14, 2013
Common standards of basal insulin titration in type 2 diabetes
Sabine Arnolds, Tim Heise, Frank Flacke, et al.
Diabetes Care
|
April 28, 2004
A direct efficacy and safety comparison of insulin aspart, human soluble insulin, and human premix insulin (70/30) in patients with type 2 diabetes
Reinhard G Bretzel, Sabine Arnolds, Jürgen Medding, et al.
Journal of Diabetes Science and Technology
|
April 9, 2015
How to Assess the Quality of Glucose Clamps? Evaluation of Clamps Performed With ClampArt, a Novel Automated Clamp Device
Carsten Benesch, Tim Heise, Oliver Klein, et al.
Diabetes Care
|
April 2, 2010
Further improvement in postprandial glucose control with addition of exenatide or sitagliptin to combination therapy with insulin glargine and metformin: a proof-of-concept study
Sabine Arnolds, Sibylle Dellweg, Janina Clair, et al.
Scientific Reports
|
December 2, 2022
Diabetes-related research priorities of people with type 1 and type 2 diabetes: a cross-sectional study in Germany
Sandra Olivia Borgmann, Marlo Verket, Veronika Gontscharuk, et al.
Plos One
|
October 1, 2014
Pharmacodynamic effects of canagliflozin, a sodium glucose co-transporter 2 inhibitor, from a randomized study in patients with type 2 diabetes
Sue Sha, Damayanthi Devineni, Atalanta Ghosh, et al.
Plos One
|
August 29, 2014
Pharmacodynamic effects of canagliflozin, a sodium glucose co-transporter 2 inhibitor, from a randomized study in patients with type 2 diabetes
Sue Sha, Damayanthi Devineni, Atalanta Ghosh, et al.
Page
of 3
Search research articles
Search
Showing results (1-10 of 25) with videos related to
Sort By:
Page
of 3
Best Practice & Research. Clinical Endocrinology & Metabolism
|
December 7, 2007
Inhaled insulin
Sabine Arnolds, Tim Heise
Lancet (London, England)
|
August 5, 2008
Basal insulin glargine vs prandial insulin lispro in type 2 diabetes
Sabine Arnolds, Klaus Rave
Diabetes Care
|
January 24, 2015
Comment on Retnakaran et al. Liraglutide and the preservation of pancreatic β-cell function in early type 2 diabetes: the LIBRA trial. Diabetes Care 2014;37:3270-3278
Sabine Arnolds, Peter T Sawicki
Journal of Diabetes Science and Technology
|
June 14, 2013
Common standards of basal insulin titration in type 2 diabetes
Sabine Arnolds, Tim Heise, Frank Flacke, et al.
Diabetes Care
|
April 28, 2004
A direct efficacy and safety comparison of insulin aspart, human soluble insulin, and human premix insulin (70/30) in patients with type 2 diabetes
Reinhard G Bretzel, Sabine Arnolds, Jürgen Medding, et al.
Journal of Diabetes Science and Technology
|
April 9, 2015
How to Assess the Quality of Glucose Clamps? Evaluation of Clamps Performed With ClampArt, a Novel Automated Clamp Device
Carsten Benesch, Tim Heise, Oliver Klein, et al.
Diabetes Care
|
April 2, 2010
Further improvement in postprandial glucose control with addition of exenatide or sitagliptin to combination therapy with insulin glargine and metformin: a proof-of-concept study
Sabine Arnolds, Sibylle Dellweg, Janina Clair, et al.
Scientific Reports
|
December 2, 2022
Diabetes-related research priorities of people with type 1 and type 2 diabetes: a cross-sectional study in Germany
Sandra Olivia Borgmann, Marlo Verket, Veronika Gontscharuk, et al.
Plos One
|
October 1, 2014
Pharmacodynamic effects of canagliflozin, a sodium glucose co-transporter 2 inhibitor, from a randomized study in patients with type 2 diabetes
Sue Sha, Damayanthi Devineni, Atalanta Ghosh, et al.
Plos One
|
August 29, 2014
Pharmacodynamic effects of canagliflozin, a sodium glucose co-transporter 2 inhibitor, from a randomized study in patients with type 2 diabetes
Sue Sha, Damayanthi Devineni, Atalanta Ghosh, et al.
Page
of 3